Status:
COMPLETED
Studying DNA and Outcome in Patients With Advanced Colorectal Cancer Treated With Fluorouracil and Oxaliplatin With or Without Bevacizumab on Clinial Trial E-3200
Lead Sponsor:
ECOG-ACRIN Cancer Research Group
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Colorectal Cancer
Eligibility:
All Genders
18-120 years
Brief Summary
RATIONALE: Studying samples of blood, urine, and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cance...
Detailed Description
OBJECTIVES: * Determine the CpG island methylation pathway markers that are adverse for survival after treatment with fluorouracil in patients with advanced colorectal adenocarcinoma treated with flu...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosis of adenocarcinoma of the colon or rectum
- Advanced disease
- Enrolled on clinical trial E-3200 and received fluorouracil and oxaliplatin
- Tumor tissue blocks available
- Routine pathology specimens (i.e., blood, urine) available
- PATIENT CHARACTERISTICS:
- Not specified
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Exclusion
Key Trial Info
Start Date :
January 3 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 30 2008
Estimated Enrollment :
350 Patients enrolled
Trial Details
Trial ID
NCT00897819
Start Date
January 3 2007
End Date
January 30 2008
Last Update
May 19 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.